Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Amortization (2019 - 2024)

Historic Amortization for Silence Therapeutics (SLN) over the last 6 years, with Q3 2024 value amounting to $204.7 million.

  • Silence Therapeutics' Amortization rose 8443.17% to $204.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $204.7 million, marking a year-over-year increase of 8443.17%. This contributed to the annual value of $100.6 million for FY2023, which is 1596.21% down from last year.
  • As of Q3 2024, Silence Therapeutics' Amortization stood at $204.7 million, which was up 8443.17% from $222.6 million recorded in Q2 2024.
  • In the past 5 years, Silence Therapeutics' Amortization registered a high of $230.5 million during Q1 2024, and its lowest value of $92.5 million during Q2 2022.
  • Moreover, its 5-year median value for Amortization was $113.0 million (2022), whereas its average is $130.6 million.
  • Its Amortization has fluctuated over the past 5 years, first soared by 32187.2% in 2020, then tumbled by 2755.51% in 2022.
  • Silence Therapeutics' Amortization (Quarter) stood at $100.9 million in 2020, then rose by 15.36% to $116.4 million in 2021, then dropped by 2.55% to $113.4 million in 2022, then fell by 11.33% to $100.6 million in 2023, then surged by 103.52% to $204.7 million in 2024.
  • Its Amortization stands at $204.7 million for Q3 2024, versus $222.6 million for Q2 2024 and $230.5 million for Q1 2024.